BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20382735)

  • 1. Limitations of peptide retro-inverso isomerization in molecular mimicry.
    Li C; Pazgier M; Li J; Li C; Liu M; Zou G; Li Z; Chen J; Tarasov SG; Lu WY; Lu W
    J Biol Chem; 2010 Jun; 285(25):19572-81. PubMed ID: 20382735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.
    Li C; Zhan C; Zhao L; Chen X; Lu WY; Lu W
    Bioorg Med Chem; 2013 Jul; 21(14):4045-50. PubMed ID: 23660015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sequence and stereochemistry reversal on p53 peptide mimicry.
    Atzori A; Baker AE; Chiu M; Bryce RA; Bonnet P
    PLoS One; 2013; 8(7):e68723. PubMed ID: 23922660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural comparison between retro-inverso and parent peptides: molecular basis for the biological activity of a retro-inverso analogue of the immunodominant fragment of VP1 coat protein from foot-and-mouth disease virus.
    Carver JA; Esposito G; Viglino P; Fogolari F; Guichard G; Briand JP; Van Regenmortel MH; Brown F; Mascagni P
    Biopolymers; 1997 Apr; 41(5):569-90. PubMed ID: 9095678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
    Sakurai K; Chung HS; Kahne D
    J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy.
    Higgins KA; Bicknell W; Keah HH; Hearn MT
    J Pept Res; 1997 Dec; 50(6):421-35. PubMed ID: 9440043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoinhibition of MDMX by intramolecular p53 mimicry.
    Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of how stress-induced MDMX phosphorylation activates p53.
    Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
    Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic retro-inverso dipeptides with two aromatic side chains. II. Conformational analysis.
    Yamazaki T; Nunami K; Goodman M
    Biopolymers; 1991 Nov; 31(13):1513-28. PubMed ID: 1814501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics.
    Guichard G; Benkirane N; Zeder-Lutz G; van Regenmortel MH; Briand JP; Muller S
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9765-9. PubMed ID: 7937888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
    Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
    Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
    Uldrijan S; Pannekoek WJ; Vousden KH
    EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.